News | October 20, 2022
Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr
Revenue from operations up 26% to Rs. 768 crores
Revenue from operations up 26% to Rs. 768 crores
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Subscribe To Our Newsletter & Stay Updated
